Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of tiroid kanseri.
Eisai, Lenvima'nın rezeke edilemeyen tiroid kanserinin klinik tedavisinde yeni standart olacağını söyledi. Sektör Lenvima konusunda oldukça iyimser ve ilacın Eisai için yeni bir nakit ineği haline gelmesi ve yıllık satışların 1 milyar doların üzerine çıkması bekleniyor.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tümör volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Şu anda çoğu tiroid kanseri türü tedavi edilebilse de, kötüleştiğinde tedavi için çok az seçenek vardır. Diferansiyel tiroid kanseri (DTC), en sık görülen malign tiroid tümörüdür ve son yıllarda görülme sıklığı giderek artmaktadır.
Lenvatinib, yeni bir bağlanma moduna sahip bir oral çoklu reseptör tirozin kinaz (RTK) inhibitörüdür. Tümör proliferasyonunda ve onkogenik sinyal yollarında rol oynayan diğer RTK'leri inhibe etmenin yanı sıra, vasküler endotelyal büyüme faktörü (VEGF) reseptör kinaz aktivitesini de seçici olarak inhibe edebilir.
